Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegylated interferons for chronic hepatitis B.

Antonio Craxi1, W Graham Cooksley

  • 1Divisione di Gastroenterologia, Instituto di Clinica Medica Policlinico, University di Palermo, Piazzale Delle Cliniche 2, 90127 Palermo, Italy.

Antiviral Research
|November 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes.

Journal of clinical and experimental hepatology·2026
Same author

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Point-of-Care Testing and Treatment of Hepatitis C Virus in Prisons: The SINTESI Project in Sicily.

Mayo Clinic proceedings. Innovations, quality & outcomes·2025
Same author

Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same journal

Evaluation of a DIVA Compliant Trivalent Negative Marker Vaccine for Foot-and-Mouth Disease in Cattle.

Antiviral research·2026
Same journal

Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.

Antiviral research·2026
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
See all related articles

Peginterferon alfa-2a (40 kDa) offers a promising new treatment for chronic hepatitis B (CHB). This therapy demonstrates superior efficacy over conventional interferon, showing rapid reductions in hepatitis B virus DNA and improved patient response.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) treatment historically relied on interferon therapy.
  • Conventional interferon has limitations including short half-life and dose-related side effects.
  • Long-term benefits of conventional interferon for CHB are less substantial than short-term gains.

Purpose of the Study:

  • To investigate the safety and efficacy of peginterferon alfa-2a (40 kDa) in treating CHB.
  • To compare the therapeutic outcomes of peginterferon alfa-2a (40 kDa) against conventional interferon in CHB patients.

Main Methods:

  • A Phase II clinical study was conducted.
  • The study evaluated peginterferon alfa-2a (40 kDa) in patients with CHB.
  • Efficacy was assessed by HBV DNA levels, HBeAg clearance, and ALT normalization.

Related Experiment Videos

Main Results:

  • Peginterferon alfa-2a (40 kDa) showed a rapid and significant reduction in hepatitis B virus (HBV) DNA levels.
  • Higher rates of HBeAg clearance and alanine aminotransferase (ALT) normalization were observed.
  • Improved treatment response was noted in patients with difficult-to-treat CHB infections.

Conclusions:

  • Peginterferon alfa-2a (40 kDa) demonstrates superior efficacy compared to conventional interferon for CHB.
  • This pegylated interferon offers improved pharmacokinetic and pharmacodynamic profiles.
  • Peginterferon alfa-2a (40 kDa) represents a promising emerging therapy for chronic hepatitis B.